Article Sidebar

Submitted
11 January 2021
Accepted
11 January 2021
Published
31 December 2019
Download
PDF
Statistic
Read Counter : 622 Download : 424

Main Article Content

Abstract

The objective of this study is to analyze the expression of E6 Humanpapilloma virus (HPV), p53, and p16INK4A in cervical adenocarcinoma grade well differentiated (WD), moderately differentiated (MD), and poorly differentiated (PD). A cross sectional study conducted at Department of Anatomic Pathology, Dr. Soetomo General Academic Hospital Surabaya Indonesia using formalin fix paraffin embedded (FFPE) from cervical normal and cervical adenocarcioma grade WD, MD, and PD. The expression of E6 HPV, p53, and p16INK4A was performed by immunohistochemistry (IHC) staining. Data were analyzed with Kruskal-Wallis and continued with Mann-Withney test. The expression of E6 HPV in the cervical adenocarcinoma showed 35.9% specimens represented negative and 64.1% specimens represented positive. There was no significant difference in the expression of E6 HPV and p53 in cervical adenocarcinoma between grade WD, MD, and PD. The p16INK4A was overexpressed, shown as diffuse appearance in 89.7% of the specimens. There was a significant difference in the expression of p16INK4A between grade WD and MD with PD. In conclusion, some of cervical adecarcinoma were not caused by infection of HPV type 16 or 18 and the expression of p16INK4A might take a role in the developing of malignancy that caused by infection of HPV.

Keywords

Grading of cervical adenocarcinoma E6 HPV p53 p16INK4A

Article Details

License

Copyright (c) 2019 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Mastutik, G., Rahniayu, A., Kurniasari, N., Rahaju, A. S., Alia, R., & Mustokoweni, S. (2019). The Expression of E6 HPV, P53 and P16ink4a at Well, Moderately, and Poorly Differentiated Cervical Adenocarcinoma. Folia Medica Indonesiana, 55(4), 295–300. https://doi.org/10.20473/fmi.v55i4.24468
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Adegoke O, Kulasingam S, Virnig B (2012). Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 21, 1031-7
  2. An HJ, Kim KR, Kim IS, et al (2005). Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol 18, 528-34
  3. Andersson S, Mints M, Wilander E (2013). Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ. Oncol Lett 6, 215-9
  4. Baalbergen A, Smedts F, Ewing P, et al (2013). HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix. Gynecol Oncol 128, 530-4
  5. Bruni L, Barrionuevo-Rosas L, Albero G, et al 2017. Human Papillomavirus and Related Diseases in Indonesia. Summary Report 27 July 2017 [Online]. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) 2017. Accessed April 12, 2018
  6. Bulk S, Berkhof J, Bulkmans NW, et al (2006). Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 94, 171-5
  7. Chaudhary A, Pandya S, Singh M, et al (2013). Identification of high-risk human papillomavirus-16 and -18 infections by multiplex PCR and their expression in oral submucous fibrosis and oral squamous cell carcinoma. Head and Neck Oncology 5, 1-10
  8. Crosbie EJ, Einstein MH, Franceschi S, et al (2013). Human papillomavirus and cervical cancer. The Lancet 382, 889-99
  9. Dowell SP, Wilson PO, Derias NW, et al (1994). Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 54, 2914-8
  10. Hietanen S, Lain S, Krausz E, et al (2000). Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A, 97, 8501-6
  11. Izadi-Mood N, Asadi K, Shojaei H, et al (2012). Potential diagnostic value of P16 expression in premalignant and malignant cervical lesions. J Res Med Sci 17, 428-33
  12. Kazlouskaya V, Shustef E, Allam SH, et al (2013). Expression of p16 protein in lesional and perilesional condyloma acuminata and bowenoid papulosis: clinical significance and diagnostic implications. J Am Acad Dermatol 69, 444-9
  13. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. (2001). Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri Int J Cancer 2001 92, 276-84
  14. Liang L, Zheng W, Liu J, et al (2016). Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. Arch Pathol Lab Med, 140, 148-52
  15. Missaoui N, Hmissa S, Frappart L, et al (2006). p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 448, 597-603
  16. Oh CM, Jung KW, Won YJ, et al (2013). Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009. PLoS One 8, e72012
  17. Pirog EC (2017). Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. Arch Pathol Lab Med 141, 1653-67
  18. Scheffner M, Werness BA, Huibregtse JM, et al (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-36
  19. Siriaunkgul S, Utaipat U, Suthipintawong C, et al (2013). HPV genotyping in adenocarcinoma of the uterine cervix in Thailand. Int J Gynaecol Obstet 123, 226-30
  20. Tornesello ML, Annunziata C, Buonaguro L, et al (2014). TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med, 12, 255
  21. Tornesello ML, Losito S, Benincasa G, et al (2011). Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol, 121, 32-42
  22. van der Horst J, Siebers AG, Bulten J, et al (2017). Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med, 6, 416-23
  23. Wells M, Östör AG, Crum CP, et al (2003). Tumours of the uterine cervix, epithelial tumours. In 'Pathology and Genetics of Tumours of the Breast and Female Genital Organs', Eds IARCPress, Lyon, 259-72

Most read articles by the same author(s)